[ad_1]
The American pharmaceutical company Gilead Science has rejected a media report on disappointing test results with the agent remdesivir for the possible treatment of Covid-19. The study in China ended prematurely due to a lack of participants and was therefore not statistically significant, Gilead said.
The Financial Times reported the process inappropriately, the World Health Organization accidentally published a draft clinical trial on the Internet. The UN organization confirmed the breakdown and said the document had been removed after the error was known.
Gilead’s stock temporarily lost more than six percent over the course of the newspaper’s report release on Wall Street. About a week ago, previously known data from a study that had not yet been released had caused euphoria on the stock exchanges: traders hoped the pandemic would be quickly overcome. There is currently no medicine or vaccine against the new coronavirus. Gilead originally developed Remdesivir to treat diseases caused by the Ebola, Marburg, Mers, and Sars viruses. (reuters)
